问题 › 下一季度我们该怎么做？ › 医疗科技与数字健康
大多数季度计划失败，是因为风险分担承诺超出了对参与率和归因结果的可观察窗口。 数字健康公司面临特定困境：结果风险的签署速度快于公司确认能否承担的速度——12个月测量窗口对上11个月销售周期。在定价前，风险分担收入份额将继续因无人能归因的原因变动，而关于每项举措回报的辩论仍将是意见之争。
大多数季度计划失败，是因为风险分担承诺超出了对参与率和归因结果的可观察窗口。 数字健康公司面临特定困境：结果风险的签署速度快于公司确认能否承担的速度——12个月测量窗口对上11个月销售周期。在定价前，风险分担收入份额将继续因无人能归因的原因变动，而关于每项举措回报的辩论仍将是意见之争。
一个季度包含固定量的临床和运营注意力，以及固定的毛利率池。大多数计划签署风险分担收入的速度，超过了公司确认能否承担结果的速度。结果不是公开失败，而是无声分流：组织交付能接触到的部分入组成员，没有人记录归因结果中被放弃的部分。
能经受接触的计划，按风险分担份额的回报对候选举措排序，用实际可用的PMPM和参与率容量核对每项，并排序以便第一项改善第二项验证所需的数据。三项真实优先级，永远胜过十二项口头优先级。
几乎总是缺失的部分是停止规则——在合同签署前而非测量窗口关闭后，定义参与率或客户流失阈值，以判定某项风险分担合同是否失效。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 上季度风险分担份额增长，而上一批次的参与率数据仍不完整，且无人正式暂停进一步签署
✓ 优先级列为PMPM目标和归因结果，但未按当前毛利率或客户流失敞口排序
✓ 没有风险分担合同附带书面的参与率或PMPM阈值来触发退出
通常会让情况更糟的做法。 签署所有通过法务和销售的风险分担份额，这会让组织的参与和结果承载能力默认决定实际组合。
It is for you if you run or finance a digital health company and last quarter's plan was partly done and nobody formally dropped anything. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Convert 2.9M contracted lives into Medicare Advantage outcomes contracts using existing payer integrations and outcomes proof points.
The leak it closes. Prevents value leakage to in-house payer solutions by demonstrating superior 12-month cohort outcomes data
The assumption it rests on. At least 4 of 34 existing health plans will sign MA outcomes contracts within 24 months — the engine put the probability at 0.75.
| Investment required | $1.8-2.4M total over 24 months |
| Expected return | 250-580% over 36 months on $62M base revenue |
| Revenue, year 1 | $2-4M incremental ARR (2-3 MA contracts) |
| Revenue, year 2 | $6-14M incremental ARR (4-7 MA contracts) |
| Revenue, year 3 | $12-25M incremental ARR (8-12 MA contracts) |
| Exit criteria | Abandon if fewer than 2 MA contracts signed by month 18 OR if engagement rate in MA pilot cohort falls below 30% OR if NCQA certification denied |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
不超过真实容量支持的数量。在大多数中小型企业中是两到三项。这个数字是算术题，不是哲学题。
先按每项消耗的容量回报排序，再按可逆性排序。两项接近时，做能停掉的那项。
这就是停止规则的作用。预先约定失败条件的计划，能依据证据而非争论调整，这是适应与漂移的区别。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית